PriceTargets.com logo

Synairgen - SNG Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 6.30 As of 04/18/2024 04:46 PM ET
▼ -0.151 (-2.34%)

This chart shows the closing price for SNG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synairgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Synairgen in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 6.30.

This chart shows the closing price for SNG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Synairgen. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/12/2021Numis SecuritiesReiterated RatingBuyGBX 990
7/20/2020FinnCapReiterated RatingCorporate
5/26/2020FinnCapReiterated RatingCorporate
5/1/2020FinnCapReiterated RatingCorporate
3/26/2020FinnCapReiterated RatingCorporate
3/18/2020FinnCapReiterated RatingCorporate
9/30/2019FinnCapReiterated RatingCorporate
7/24/2019FinnCapReiterated RatingCorporate
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Synairgen logo
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Read More

Today's Range

Now: GBX 6.30
Low: 6.05
High: 6.89

50 Day Range

MA: GBX 5.32
Low: 4.50
High: 7.54

52 Week Range

Now: GBX 6.30
Low: 4
High: 14.90

Volume

248,818 shs

Average Volume

373,694 shs

Market Capitalization

£12.68 million

P/E Ratio

N/A

Dividend Yield

1.53%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Synairgen?

The following sell-side analysts have issued stock ratings on Synairgen in the last year:
View the latest analyst ratings for SNG.

What is the current price target for Synairgen?

0 Wall Street analysts have set twelve-month price targets for Synairgen in the last year. has the lowest price target set, forecasting a price of £100,000 for Synairgen in the next year.
View the latest price targets for SNG.

What is the current consensus analyst rating for Synairgen?

Synairgen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNG.

What other companies compete with Synairgen?

Other companies that are similar to Synairgen include Realm Therapeutics, Sareum, NetScientific, Ondine Biomedical and ImmuPharma. Learn More about companies similar to Synairgen.

How do I contact Synairgen's investor relations team?

Synairgen's physical mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The company's listed phone number is +44-23-80512800. The official website for Synairgen is www.synairgen.com. Learn More about contacing Synairgen investor relations.